---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-076153"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:26:26.291815+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q2 2025 revenue $20.2M (+26% YoY); net loss narrows to $9.9M; reaffirms FY2025 guidance $85M-$88M

## Summary
- Revenue $20.2M (+26% YoY); OviTex PRS product revenue up 53% YoY.
- Net loss $9.9M vs $12.6M in prior-year quarter; operating loss $9.1M improved from $11.6M.
- Gross margin improved to 69.8% vs 68.8% due to lower excess/obsolete inventory charge.
- Appointed Jeffrey Blizard as President effective June 2025 to strengthen commercial leadership.
- Reaffirmed FY2025 revenue guidance of $85M-$88M (23-27% YoY growth); cash $35.0M.

## SEC filing metadata
- accession: 0001104659-25-076153
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465925076153/0001104659-25-076153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465925076153/tm2522957d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-076153
- JSON: https://secwatch.observer/filing/0001104659-25-076153.json
- Plain text: https://secwatch.observer/filing/0001104659-25-076153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.